Infant Bacterial Therapeutics AB
Developing novel biotherapeutics for premature infant diseases through rigorous clinical trials.
Overview
- 5–9
- Employees
- ≤1K SEK
- Revenue
- 2011
- Founded
Key Decision Makers
Staffan Strömberg
CEO
Thomas J. Schnitzer
Chief Scientific Officer
Kristina Sjöblom Nygren
Board Member
Sanjiv Sharma
Head of Medical Affairs
+10 more contacts in Funnelfeedr
Description
Infant Bacterial Therapeutics AB (IBT) is a specialized pharmaceutical company focused on developing and commercializing novel drugs specifically targeting diseases affecting premature infants. The company addresses significant unmet medical needs, such as Necrotizing Enterocolitis (NEC), gastroschi...